The Value of Combined Detection of D-dimer and CD62p in Judging the Severity of Acute Cerebral Infarction and Short-Term Prognosis

Min Xu,1 Xiao-ying He,2 and Pan Huang3

1Department of Neurology, The Second People’s Hospital of Deyang City, No. 340 Minjiang West Road, Deyang, Sichuan 618000, China
2Department of Neurology, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou, Sichuan 646000, China
3Department of Neurology, People’s Hospital of Deyang City, No. 173 TaiShan North Road, Deyang, Sichuan 618000, China

Correspondence should be addressed to Pan Huang; 1032857970@qq.com

Received 23 December 2020; Revised 2 January 2021; Accepted 7 January 2021; Published 18 January 2021

Academic Editor: Yuzhen Xu

Copyright © 2021 Min Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To explore the value of combined detection of peripheral blood P-selectin (CD62p) and D-dimer (D-dimer) in the judgment of acute cerebral infarction severity and short-term prognosis. Methods. 268 patients with acute cerebral infarction from February 2015 to February 2019 were selected as the observation group. According to the National Institute of Health stroke scale, there were 90 cases (SCI group), 88 cases (MOCI group), and 90 cases (MICI group) in the severe, moderate, and mild cerebral infarction groups, respectively. In the same period, 80 cases of healthy people served as the Normal group. Use flow cytometry to detect CD62p in peripheral blood and magnetic bead method to detect D-dimer level within 24 hours of onset. Logistic regression was used to analyze whether the two are factors affecting the short-term prognosis of acute cerebral infarction, and the ROC curve was drawn to evaluate the value of the combined detection of the two in the short-term prognosis of patients with acute cerebral infarction. Results. Peripheral blood D-dimer and CD62p levels (2.30 ± 0.51 ng/l, 27.58 ± 5.56 ng/l) in the SCI group were higher than those in the MOCI group (2.95 ± 0.76 ng/l, 34.03 ± 5.29 ng/l) and the MICI group (1.87 ± 0.40 ng/l, 19.60 ± 3.98 ng/l); the difference between the groups was statistically significant (P < 0.05). Logistic regression analysis showed that D-dimer and CD62p were independent risk factors affecting the poor prognosis of patients with acute cerebral infarction (OR values were 3.752 and 1.213, and 95% CI were 1.612-7.934 and 1.093-1.342, respectively, both P < 0.05). The AUC of D-dimer combined with CD62p for predicting poor prognosis of acute cerebral infarction is 0.859, which is better than D-dimer and CD62p alone. Conclusion. Peripheral blood D-dimer combined with CD62p detection is helpful for the risk stratification and short-term prognosis assessment of patients with acute cerebral infarction. Clinical detection is of great significance for the prevention and monitoring of disease development.

1. Introduction

Acute cerebral infarction (ACI) is a common clinical disease and frequently occurring disease. Due to the nonrenewable nature of neurons, cerebral infarction has a very high disability rate and recurrence rate, which brings a serious burden to society and families. Therefore, it is very important to predict the early stage of high-risk patients with cerebral infarction and actively rescue the ischemic penumbra in the early stage after cerebral infarction, restore the blood supply of brain cells to slow down the brain cell damage, and improve the clinical treatment rate of patients [1]. Studies have found that platelet activation, coagulation system, and fibrinolytic system imbalance are the main causes of cerebral thrombosis [2, 3]. P-selectin (CD62p), as a glycoprotein on the surface of platelets, can reflect the level of platelet activation, and D-dimer is a clear marker that reflects the high specificity of thrombosis and activation of the fibrinolytic system, which
2. Materials and Methods

2.1. Clinical Data. 268 patients with acute cerebral infarction who were hospitalized in the Department of Neurology of our hospital from February 2015 to February 2019 were selected as the cerebral infarction group, including 148 males and 120 females, aged 45-82 (68.78 ± 9.72) years old. All selected cases meet the diagnostic criteria for acute ischemic stroke [4]. According to the diagnosis results of hematology, imaging, and cardiac examination, TOAST classification was carried out and confirmed by two researchers for consistency and acute cerebral infarction of the internal carotid artery system (TOAST etiology classification is atherosclerotic thrombosis). Also, exclude posterior circulation cerebral infarction, chronic obstructive pulmonary disease, ischemic heart disease, rheumatic heart disease, congenital heart disease, bacterial endocarditis and atrial fibrillation, autoimmune system disease, malignant tumor, infection, severe medical diseases (such as pulmonary embolism, venous sinus thrombosis, deep vein thrombosis), and women who have a history of taking estrogen caused by occlusion of the vertebral-basal artery system. The content of D-dimer in plasma was detected by the magnetic bead method (normal value: 0-1 μg/ml).

2.2. Specimen Collection and Measurement Methods. All subjects were taken fasting anterior elbow venous blood before receiving treatment after admission 3 ml. Among them, the EDTA anticoagulant tube was used to separate and extract the plasma, and the anticoagulant tube was not added to separate and extract the serum and stored in the refrigerator at -20°C. The CD62p level in serum was detected by flow cytometry (flow cytometer was American Applied Biosystems; the kit was Shanghai Xuanhao Technology Co., Ltd., operated according to the instructions). The content of D-dimer in plasma was detected by the magnetic bead method (normal value: 0-1 μg/ml).

2.3. Prognosis Follow-Up. After 3 months of onset, follow-up by telephone or outpatient service, evaluate the functional prognosis of the patients according to the mRS score, and group them according to the prognosis of the patients. mRS score ≤ 2 is a good prognosis group, and mRS score > 2 is a poor prognosis group. Analyze the affected patient prognostic factors. The blind collection is used for data collection.

2.4. Statistical Methods. Using the SPSS17.0 statistical software, the measurement data is expressed as x ± s, the independent sample t-test is used for the comparison of the two groups, the ANOVA analysis is used for the comparison of...
multiple comparisons, and the LSD-t method is used for the pairwise comparison. Logistic regression was used to analyze whether D-dimer and CD62p are factors affecting the prognosis of patients with acute cerebral infarction, and the ROC curve was drawn to calculate the area under the curve (AUC). P < 0.05 indicates that the difference is statistically significant.

3. Result

3.1. Comparison of Baseline Data between the Observation Group and Control Group. There was no significant difference in the clinical data and laboratory examination between the observation group and the control group (P > 0.05) (Table 1).

3.2. The Levels of D-dimer and CD62p in the Peripheral Blood of the Observers Were Compared. The results showed that the levels of D-dimer and CD62p in the cerebral infarction group were higher than those in the normal group, and the difference was statistically significant (P < 0.05). The differences between the SCI group, MOCI group, and MICI group are also statistically significant (Table 2).

3.3. Correlation Analysis of D-dimer, CD62p Levels, and NIHSS Scores in the Observation Group. The results showed that D-dimer, CD62p, and NIHSS scores were all positively correlated (r = 0.455, 0.707; P < 0.05) (Table 2 and 3).

3.4. Factors Affecting the Prognosis of Patients with Acute Cerebral Infarction. WithmRS ≤2 points in March as the good prognosis group (190 cases), mRS>2 points as the poor prognosis group (78 cases); D-dimer, CD62p, and general clinical data were used as independent variables for logistic regression analysis. It is shown that smoking history, D-dimer, and CD62p are all independent predictors of poor prognosis, as shown in Table 4.

3.5. The Predictive Value of D-dimer and CD62p on the Poor Prognosis of Acute Cerebral Infarction. The AUC of D-dimer and CD62p alone in predicting poor prognosis of acute cerebral infarction were 0.712 and 0.848 (P < 0.05), respectively. The combined detection of the two to predict the poor prognosis of acute cerebral infarction AUC was 0.859 (P < 0.05) (Table 5 and Figure 4).

4. Discussion

Acute cerebral infarction is a common clinical thromboembolic disease with an extremely high risk of disability, death, and recurrence. Therefore, it is of great significance to actively seek specific markers that can predict the severity and prognosis of the disease. Most of the TOAST etiological classification of cerebral infarction is atherosclerosis, and its pathological basis is platelets. Studies have found that platelet activation is closely related to the occurrence and development of thrombosis. Cerebral infarction is based on atherosclerotic plaques. Due to changes in hemodynamics or blood contents, platelet activation is intensified, forming platelet-vininogen thrombus, which blocks blood vessels and causes infarction [6–8].

Various reasons cause the damaged blood vessel wall to contract and change the local hemodynamic characteristics, which leads to the adhesion of platelets to the exposed subendothelial tissue under the action of plasma von Willebrand factor (VWF). The stimulation of collagen or thrombin released by endothelial cells undergoes morphological changes, and further release reaction and

### Table 1: Comparison of baseline data between observation group and control group.

| Item          | Observation group (n = 268) | Normal group (n = 80) | P   |
|---------------|-----------------------------|-----------------------|-----|
| Age (years)   | 64.42 ± 8.72                | 63.97 ± 8.55          | 0.68|
| Sex (M/F)     | 136/132                     | 38/32                 | 0.85|
| Smoke (n, %)  | 145 (54.10%)                | 47 (58.75%)           | 0.76|
| Hypertension (n, %) | 51 (19.02%)             | 15 (18.75%)           | 0.46|
| Diabetes (n, %) | 41 (15.29%)                | 12 (15.00%)           | 0.09|
| SCr (μmol/l)  | 52.23 ± 6.46                | 51.89 ± 6.21          | 0.67|
| UA (μmol/l)   | 354.47 ± 37.15              | 361.12 ± 39.47        | 0.17|
| TC (mmol/l)   | 4.87 ± 0.42                 | 4.91 ± 0.43           | 0.45|
| TG (mmol/l)   | 1.22 ± 0.24                 | 1.27 ± 0.28           | 0.07|
| HDL-C (mmol/l)| 0.93 ± 0.23                 | 0.96 ± 0.24           | 0.61|
| LDL-C (mmol/l)| 2.89 ± 0.43                 | 2.83 ± 0.40           | 0.45|
| AST/ALT       | 0.75 ± 0.23                 | 0.72 ± 0.22           | 0.65|
| BMI (kg/m²)   | 22.56 ± 1.23                | 22.74 ± 1.27          | 0.69|
| Drinker (n, %) | 82 (30.59%)                | 22 (27.5%)            | 0.58|

BMI: body mass index; TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low high-density lipoprotein-cholesterol.

| Item          | NIHSS scores | D-dimer (μg/ml) | CD62p (ng/l) |
|---------------|--------------|----------------|--------------|
| Normal        | 80           | 0              | 0.87 ± 0.23  | 16.20 ± 3.26 |
| SCI           | 90           | 4.60 ± 0.76    | 1.87 ± 0.40* | 19.60 ± 3.98*|
| MOCI          | 88           | 12.40 ± 2.56   | 2.30 ± 0.51* | 27.58 ± 5.56*|
| MICI          | 90           | 18.79 ± 2.98   | 2.95 ± 0.76**| 34.03 ± 5.29**|
| P             | 0.00         | 0.00           | 0.00         |

*The MICI group compares with the normal group P < 0.05; *The MOCI group compares with the MICI group P < 0.05; **The SCI group compares with the MICI group P < 0.05.

| Item          | NIHSS score | r   | P   |
|---------------|-------------|-----|-----|
| D-Dimer       | 0.455       | 0.00| 0.00|
| CD62p         | 0.707       | 0.00| 0.00|
arachidonic acid metabolism occur. The ADP secreted by 
the release reaction and the metabolism of arachidonic 
acid to form thromboxane A2 can activate intracellular 
pathways to make Ca ion flow, which causes the bridging 
of platelets and fibrin to cause aggregation, and finally, 
plasma fibrinogen participates in the aggregation to form 
thrombus. The platelet adhesion-deformation-release-
aggregation reaction in this process is the platelet activa-
tion reaction [9, 10]. It is precisely because platelet activa-
tion has such an important role; this study is based on this 
observation in order to find new ways to predict the sever-
ity and prognosis of the disease.

CD62p is a glycoprotein distributed on α particles in 
stationary platelets. When platelets are activated, α parti-
cles quickly fuse with the platelet membrane and release, 
so that CD62p is redistributed on the surface of platelets 
[11]. Studies have found that the concentration peak is 
reached 10 minutes after platelet activation, so it can be 
used as a specific marker for evaluating platelet activation

| Item       | OR  | 95% CI            | P    |
|------------|-----|-------------------|------|
| Age        | 1.052 | 0.883-1.256       | 0.556|
| Hypertension | 7.281 | 0.458-113.230    | 0.152|
| Diabetes    | 4.352 | 0.426-44.684      | 0.214|
| Smoke       | 4.102 | 1.086-15.234      | 0.035|
| Drink     | 0.715 | 0.064-8.231       | 0.724|
| SCr          | 0.269 | 0.023-3.487       | 0.312|
| BMI         | 1.213 | 0.115-12.485      | 0.885|
| D-Dimer     | 3.572 | 1.612-7.934       | 0.002|
| CD62p       | 1.213 | 1.093-1.342       | 0.003|

| Item       | AUC  | Standard error  | 95% CI        | P   |
|------------|------|-----------------|---------------|-----|
| D-Dimer    | 0.712 | 0.033           | 0.647-0.777   | 0.026|
| CD62p      | 0.848 | 0.028           | 0.794-0.902   | 0.019|
| D-Dimer+CD62p | 0.859 | 0.027          | 0.807-0.911   | 0.005|

status and thrombosis. Okada used mice and baboons to 
establish a model of cerebral ischemia and found that 
the expression of CD62p increased after 1 hour of cerebral 
ischemia, reaching a peak at 8 to 24 hours and lasting for 
3 to 5 days [12]. The domestic scholar HUANG Tong 
dynamically detects CD62p in patients with acute cerebral 
infarction, and the results are basically consistent with 
OKada [13]. Cha observation of 45 patients with acute 
cerebral infarction showed that the upregulation of
CD62p is related to the clinical deterioration of patients with acute cerebral infarction [14]. In addition, acute cerebral infarction is often associated with dysfunction or disorder of the fibrinolytic system. D-dimer is a specific degradation product of cross-linked fibrin, the increase of peripheral blood D-dimer indicates the enhancement of in vivo fibrinolytic activity. Studies have found that D-dimer will only increase in plasma after thrombosis in the body, so it can be used as a specific molecular marker for the diagnosis of thrombosis. Studies have shown that D-dimer is related to the onset and recurrence of coronary heart disease and is also related to cerebral venous sinus thrombosis [15, 16].

This study shows that the levels of CD62p and D-dimer in patients with acute cerebral infarction are significantly higher than those in the normal control group, indicating that the two can be used as markers of acute cerebral infarction thrombosis, which is consistent with other relevant experimental conclusions [17–19]. The levels of D-dimer and CD62p can be dynamically monitored during clinical thrombolysis to evaluate whether thrombus fusion is possible. The levels of D-dimer and CD62p in the SCI group were higher than those in the MOCI group and the MICI group, and the differences were statistically significant (P < 0.05), indicating that the higher the degree of platelet activation, the stronger the platelet adhesion and aggregation ability, and the easier to form arteries. Thrombus causes local brain tissue blood supply to be interrupted to form infarcts. Logistic regression analysis shows that D-dimer and CD62p are independent risk factors affecting the prognosis of patients with cerebral infarction. ROC curve analysis shows that peripheral blood D-dimer and CD62p levels have a higher predictive value for the poor prognosis of patients with acute cerebral infarction, which is consistent with the conclusions of other scholars [20, 21]. Therefore, the detection of peripheral blood D-dimer combined with CD62p in patients with acute cerebral infarction is timely, convenient, and economical and can early assess the risk stratification and prognosis of patients with acute cerebral infarction. However, the sample size of the cases collected in this study is small and cannot be monitored dynamically, which needs to be further improved.

Data Availability
All data, models, and code generated or used during the study appear in the submitted article.

Conflicts of Interest
The authors declare that they have no financial or other conflicts of interest in relation to this research and its publication.

References
[1] X. Yi, Z. Han, Q. Zhou, J. Lin, and P. Liu, "20-Hydroxyeicosatetraenoic acid as a predictor of neurological deterioration in acute minor ischemic stroke," Stroke, vol. 47, pp. 3045–3047, 2016.
[2] A. Mizuma, K. Iijima, S. Kohara et al., "Effect of atorvastatin co-treatment on inhibition of platelet activation by clopidogrel in patients with ischemic stroke," International Journal of Stroke, vol. 10, pp. E90–E91, 2015.
[3] H. Tohgi, S. Konno, S. Takahashi, D. Koizumi, R. Kondo, and H. Takahashi, "Activated coagulation/fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels," Thrombosis research, vol. 100, pp. 373–379, 2000.
[4] Y. Pan, W. Chen, Y. Xu et al., "Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis," Circulation, vol. 135, no. 1, pp. 21–33, 2017.
[5] M. P. Thompson, Z. Luo, J. Gardiner, J. F. Burke, A. Nickles, and M. J. Reeves, "Quantifying selection bias in National Institute of Health Stroke Scale data documented in an acute stroke registry," Circulation: Cardiovascular Quality and Outcomes, vol. 9, pp. 286–293, 2016.
[6] S. Watanabe, F. Usui-Kawanishi, T. Komada et al., "ASC regulates platelet activation and contributes to thrombus formation independent of NLRP3 inflammasome," Biochemical and Biophysical Research Communications, vol. 531, pp. 125–132, 2020.
[7] L. J. Ren, Q. Li, T. You et al., "Humanin analogue, HNG, inhibits platelet activation and thrombus formation by stabilizing platelet microtubules," Journal of Cellular and Molecular Medicine, vol. 24, no. 8, pp. 4773–4783, 2020.
[8] D. Guo, Z. Zhu, C. Zhong et al., "Prognostic metrics associated with inflammation and atherosclerosis signaling evaluate the burden of adverse clinical outcomes in ischemic stroke patients," Clinical chemistry, vol. 66, pp. 1434–1443, 2020.
[9] A. Ruban, N. Daya, A. L. Schneider et al., "Liver enzymes and risk of stroke: the atherosclerosis risk in communities (ARIC) study," Journal of stroke, vol. 22, pp. 357–368, 2020.
[10] D. Sagridis, G. Georgiopoulous, I. Leventis et al., "Antithrombotic treatment in patients with stroke and supracardiac atherosclerosis," Neurology, vol. 95, pp. e499–e507, 2020.
[11] X. Zhong, Z. Cao, J. Song, Y. Liu, and Q. Guo, "Relationship of platelet glycoprotein Iib/IIa and CD62P with hypercoagulable state after oncologic surgery," Clinical and Applied Thrombosis/Hemostasis, vol. 26, p. 1076029620977906, 2020.
[12] Y. Okada and B. R. Copeland, "P-selectin and intercellular adhesion molecules-1 expression after focal brain ischemia and reperfusion," Stroke, vol. 25, no. 1, pp. 202–211, 1994.
[13] X. S. Huang, Q. D. Yang, Y. H. Liu, and Z. J. Liu, "Changes of plasma CD 62 p levels in patients with acute cerebral infarction," Journal of Central South University. Medical sciences, vol. 29, no. 4, pp. 445–447, 2004.
[14] J. K. Cha, M. H. Jeong, E. K. Kim et al., "Surface expression of P-selectin on platelets is related with clinical worsening in acute ischemic stroke," Journal of Korean medical science, vol. 17, no. 6, pp. 811–816, 2002.
[15] E. Soyode, W. Pritchard, M. Hayman, A. Davenport, P. Sivasothy, and W. Thomas, "Validation of the age-adjusted D-dimer in an ambulatory deep vein thrombosis diagnostic service: beware of superficial thrombophlebitis," British Journal of Haematology, vol. 191, pp. e94–e96, 2020.
[16] R. Meng, X. Wang, M. Hussain et al., “Evaluation of plasma D-dimer plus fibrinogen in predicting acute CVST,” International Journal of Stroke, vol. 9, no. 2, pp. 166–173, 2014.

[17] H. Li, G. N. Bi, and C. M. Luo, “The expression of P-selectin and the change of myeloperoxidase activity in rats with cerebral ischemia-reperfusion,” Chinese Journal of Cerebrovascular Disease, vol. 2, no. 10, pp. 454–458, 2005.

[18] L. T. Zhang, X. J. Yang, and M. Pang, “The changes of serum soluble E-selectin and P-selectin levels in patients with ischemic stroke,” Chinese Journal of Cerebrovascular Diseases, vol. 3, no. 2, pp. 69-70, 2006.

[19] N. Li, C. H. Ren, F. Sun, and X. M. Ji, “Changes of plasma fibrinogen, D-dimer and antithrombin III levels in patients with acute cerebral infarction,” Chinese Journal of Cerebrovascular Diseases, vol. 10, no. 5, pp. 268–272, 2013.

[20] F. Lu and Z. H. Wang, “Role of CD62p in the diagnosis of acute brain infarction disease,” Journal of Capital Medical University, vol. 36, no. 5, pp. 714–717, 2015.

[21] T. Leng and Z. G. Xiong, “Treatment for ischemic stroke: from thrombolysis to thrombectomy and remaining challenges,” Brain circulation, vol. 5, no. 1, p. 8, 2019.